The UK Regenerative Medicine Platform (UKRMP) is pleased to present an exciting programme of exceptional research in the field of Regenerative Medicine. Aimed at bringing together an international audience of researchers with a desire to hear about research, tools and techniques to progress cutting edge science from bench to bedside. Hear from experts in the field, and join us to build your network, as we celebrate 10 years of UK Regenerative Medicine translational research.
Meeting Aims:
The UK Regenerative Medicine Platform (UKRMP) was established over 10 years ago to try to address the Key Translational Challenges of Regenerative Medicine. UKRMP Regenerative Medicine 2023, aims to showcase the progress of UK translational regenerative medicine research and hopes to build on the success of UKRMP outputs, industrial collaborations and clinical application.
Who Should Attend?
Anyone with an interest in Regenerative Medicine, tools and techniques for cutting edge science and progress from bench to bedside.
Confirmed Speakers:
- Rawiya Al Hosni, Postdoctoral Researcher, University of Cambridge, UK
- Ivana Barbaric, Professor, University of Sheffield, UK
- Roger Barker, Professor, University of Cambridge, UK
- Jacqueline Barry, Chief Clinical Officer, Cell and Gene Therapy Catapult, UK
- Catherine Beltran-Rendon, Postdoctoral Researcher, Loughborough University, UK
- Robin Buckle, Chief Science Officer, Medical Research Council, UK
- Neil Carragher, Professor, University of Edinburgh, UK
- Jonathan Dawson, Associate Professor, University of Southampton, UK
- Charlotte Durkin, Head of Multimodal and Multiscale Biology, Medical Research Council, UK
- Alicia El Haj, Professor, University of Birmingham, UK
- Elaine Emmerson, RCUK/UKRI Innovation Fellow & Chancellor’s Fellow, University of Edinburgh, UK
- Stuart Forbes, Professor, University of Edinburgh, UK
- Victoria Gadd, Postdoctoral Research Fellow, University of Edinburgh, UK
- Cedric Ghevaert, Professor, University of Cambridge, UK
- David Hay, Professor, University of Edinburgh, UK/Founder, Chairman and CEO, Stimuliver, Denmark
- Zoe Hewitt, Co-Founder and CEO, Regenerative Cell Therapy Consulting Ltd, UK
- Yuki Ishii, Postdoctoral Researcher, University College London, UK
- Agnieszka Janeczek, Founder and CEO, Renovos, UK
- Joanne Jones, Associate Professor, University of Cambridge, UK
- Janos Kanczler, Lecturer, University of Southampton, UK
- Owen Laing, PhD Student, University of Sheffield, UK
- Hannah Levis, Senior Lecturer, University of Liverpool, UK
- Andrew McCaskie, Professor, University of Cambridge, UK
- Florian Merkle, Principle Investigator, University of Cambridge, UK
- Pierre-Alexis Mouthuy, Associate Professor, University of Oxford, UK
- Marko Nikolic, MRC Clinician Scientist Fellow, University College London, UK
- Malin Palmer, Professor, Lund University, Sweden
- Rachael Pearson, Professor, King’s College London, UK
- Graziella Pellegrini, Professor, University of Modena and Reggio Emilia, Italy
- Jelle Penders, Co-founder and CEO, SPARTA Biodiscovery Ltd, UK
- Felicity Rose, Professor, University of Nottingham, UK
- Kourosh Saeb-Parsy, Professor, University of Cambridge, UK
- Manuel Salmeron-Sanchez, Professor, University of Glasgow, UK
- Stefan Schoenfelder, Career Progression Fellow, Babraham Institute, UK
- Hazel Screen, Professor, Queen Mary University of London, UK
- Molly Stevens, Professor, University of Oxford and Imperial College London, UK
- Sarah Waters, Professor, University of Oxford, UK
- Lisa White, Associate Professor, University of Nottingham, UK
- Jonathan Wojciechowski, Postdoctoral Research Associate, Imperial College London, UK
Key Information and Dates
Registration Closes: Midnight Monday 30th October 2023
Printed Poster Deadline: Wednesday 1 November 2023
Event Sponsors
For details on our remaining sponsorship opportunities please contact us
As human pluripotent stem cell (hPSC) derived-cell therapies progress into the clinic, one of the challenges we are addressing surrounds the safety of hPSC derivates for use in cellular therapies. A key aspect of this work entails assessing how cells that acquire common chromosomal abnormalities can overtake the existing normal wild-type population.
Researchers (Christopher Price, PhD and Dylan Stavish) from the Pluripotent Stem Cell and Engineered Cell (PSEC) Hub based at The University of Sheffield, led by Dr Ivana Barbaric, describe in a recent Developmental Cell article, a selection mechanism that facilitates genetically variant cells achieving clonal dominance by eliminating wild-type through YAP mediated cell competition.
https://lnkd.in/dYNDdy8b